Cointime

Alto Neuroscience

company

About

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

  • 1 - 10

Highlights

Total Funding Amount
$67M
Funding Rounds
3
Investors
3

Details

Last Funding Type
Series B
Industries
Artificial Intelligence,Biopharma,Biotechnology,Health Care,Neuroscience
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$67M
Alto Neuroscience has raised a total of $67M in funding over 2 rounds. Their latest funding was raised on Oct 25, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 25, 2022 Series B $35M 2 — — Detail
May 24, 2021 Series B — 1 — — Detail
May 3, 2021 Series A $32M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
3
Alto Neuroscience is funded by 3 investors. Korify Capital and Gaingels are the most recent investors.
Investor Name Lead Investor Funding Round
Korify Capital — Series B
Gaingels — Series B
NJF Capital — Series B
Cointime
เนื้อหา
บริษัท